2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma
- PMID: 36708540
- DOI: 10.3171/2022.12.JNS221954
2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma
Abstract
Objective: Adult brainstem gliomas (BSGs) are rare tumors of the CNS that are poorly understood. Upregulation of the oncometabolite 2-hydroxyglutarate (2HG) in the tumor indicates the mutation of isocitrate dehydrogenase (IDH), which can be detected by magnetic resonance spectroscopy (MRS). Although histological examination is required for the definitive diagnosis of BSG, 2HG-optimized MRS (2HG-MRS) may be useful, considering the difficult nature of brainstem lesion biopsy. The aim of this study was to evaluate the utility of 2HG-MRS for diagnosing IDH-mutant adult BSG.
Methods: Patients with a radiographically confirmed brainstem tumor underwent 3T MRS. A single voxel was set in the lesion with reference to the T2 or fluid-attenuated inversion recovery image and analyzed according to the 2HG-tailored MRS protocol (point-resolved spectroscopic sequence; echo time 35 msec). All patients underwent intraoperative navigation-guided or CT-guided stereotactic biopsy for histopathological diagnosis. The status of IDH and H3K27M mutations was confirmed by immunohistochemistry and direct DNA sequencing. In addition, the authors examined the relationship between patients' 2HG concentrations and survival time.
Results: Ten patients (7 men, 3 women; median age 33.5 years) underwent 2HG-MRS and biopsy. Four patients had an H3K27M mutation and 4 had an IDH1 mutation (1 R132H canonical IDH mutation, 2 R132S and 1 R132G noncanonical IDH mutations). Two had neither H3K27M nor IDH mutations. The H3K27M and IDH mutations were mutually exclusive. Most tumors were located in the pons. There was no significant radiological difference between mutant H3K27M and IDH on a conventional MRI sequence. A 2HG concentration ≥ 1.8 mM on MRS demonstrated 100% (95% CI 28%-100%) sensitivity and 100% (95% CI 42%-100%) specificity for IDH-mutant BSG (p = 0.0048). The median overall survival was 10 months in IDH-wild-type BSG patients (n = 6) and could not be estimated in IDH-mutant BSG patients (n = 4) due to the small number of deaths (p = 0.008).
Conclusions: 2HG-MRS demonstrated high sensitivity and specificity for the prediction of IDH-mutant BSG. In addition, 2HG-MRS may be useful for predicting the prognosis of adult BSG patients.
Keywords: 2-hydroxyglutarate; 2HG; IDH mutation; adult brainstem glioma; diagnosis; magnetic resonance spectroscopy; oncology; tumor.
Similar articles
-
Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.J Neurosurg. 2018 Feb;128(2):391-398. doi: 10.3171/2016.10.JNS161793. Epub 2017 Mar 3. J Neurosurg. 2018. PMID: 28298040
-
Association between accumulation of 2-hydroxyglutarate detected by MR spectroscopy and preoperative seizure in IDH-mutant glioma.J Neurosurg. 2024 Oct 25;142(3):712-721. doi: 10.3171/2024.6.JNS24166. Print 2025 Mar 1. J Neurosurg. 2024. PMID: 39454209
-
Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.J Neurosurg. 2019 Jan 4;132(1):180-187. doi: 10.3171/2018.8.JNS181207. Print 2020 Jan 1. J Neurosurg. 2019. PMID: 30611146
-
2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.Neuro Oncol. 2018 Nov 12;20(12):1573-1583. doi: 10.1093/neuonc/noy113. Neuro Oncol. 2018. PMID: 30020513 Free PMC article.
-
2-Hydroxyglutarate magnetic resonance spectroscopy for preoperative IDH molecular profiling - A review of the literature and real-world clinical translation in a busy neurosurgical neuro-oncology unit.J Clin Neurosci. 2025 Mar;133:111062. doi: 10.1016/j.jocn.2025.111062. Epub 2025 Jan 29. J Clin Neurosci. 2025. PMID: 39986710 Review.
Cited by
-
-New frontiers in domain-inspired radiomics and radiogenomics: increasing role of molecular diagnostics in CNS tumor classification and grading following WHO CNS-5 updates.Cancer Imaging. 2024 Oct 7;24(1):133. doi: 10.1186/s40644-024-00769-6. Cancer Imaging. 2024. PMID: 39375809 Free PMC article. Review.
-
Astrocytomas IDH-mutant of posterior cranial fossa, clinical presentation, imaging features and onco-functional balance in surgical management.Neurosurg Rev. 2025 Feb 27;48(1):271. doi: 10.1007/s10143-025-03436-x. Neurosurg Rev. 2025. PMID: 40014162 Free PMC article.
-
Association of preoperative seizures with reduced expression of soluble CD163, an M2 macrophage marker, in the cerebrospinal fluid in isocitrate dehydrogenase wild-type glioblastoma.J Neurooncol. 2025 Jan;171(1):95-103. doi: 10.1007/s11060-024-04837-6. Epub 2024 Oct 8. J Neurooncol. 2025. PMID: 39377994
-
Clinical outcome, radiological findings, and genetic features of IDH-mutant brainstem glioma in adults.Acta Neurochir (Wien). 2024 Jun 12;166(1):263. doi: 10.1007/s00701-024-06154-3. Acta Neurochir (Wien). 2024. PMID: 38864949
-
Race and "omic" data in glioma: A systematic review of contemporary research to explore the digital divide.Neurooncol Pract. 2025 Jan 31;12(4):585-599. doi: 10.1093/nop/npaf016. eCollection 2025 Aug. Neurooncol Pract. 2025. PMID: 40814428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous